+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy

The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy

Aids Research and Human Retroviruses 27(12): 1299-1309

We investigated whether polymorphisms in human candidate genes could be associated with a different risk of developing lipodystrophy and dyslipidemia in HIV-infected patients starting combination antiretroviral therapy (cART). Genomic DNA samples from white HIV-1-infected patients were analyzed for seven polymorphisms located in the MDR1, TNF-α, APM1, APOE, and LPL genes. Lipid data were retrospectively collected beginning with the initiation of cART. Lipodystrophy was assessed cross-sectionally and then prospectively. The association with lipodystrophy and National Cholesterol Evaluation Program Adult Treatment Panel III-defined lipid thresholds was analyzed using survival analysis and logistic regression. One-hundred and seventy-four patients were genotyped. In 151 patients assessed for lipodystrophy, MDR1 3435 T homozygosis was associated with a higher hazard (adjusted hazard ratio, aHR, versus CT 0.25; p=0.02) and tumor necrosis factor (TNF)-α 308 G homozygosis with a lower hazard (vs. AA aHR 2.14; p=0.04) of developing trunk fat accumulation after adjusting for gender and initial cART type. The TNF 238 GG genotype was associated with a higher risk of developing low HDL-cholesterol levels (adjusted odd ratio, aOR, 5.91; p=0.01) while patients carrying the LPL S477X mutation were at lower risk of reaching high non-HDL-cholesterol levels (aOR 0.39; p=0.05). The APOEe3/3 genotype patients were at lower risk (aOR 0.26, p=0.015), whereas the adiponectin 276 GT carriers were at higher risk of developing hypertriglyceremia (vs. GG aOR 3.10; p=0.04). Knowledge of the effect of genetic determinants on dyslipidemia and lipodystrophy may prompt the investigation of potential pathogenetic mechanisms and might eventually be used for guiding individualized treatment decisions.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 056308910

Download citation: RISBibTeXText

PMID: 21595566

DOI: 10.1089/aid.2010.0172

Related references

Polymorphisms in adiponectin receptor genes are associated with lipodystrophy-related phenotypes in HIV-infected patients receiving antiretroviral therapy. HIV Medicine 16(8): 494-501, 2016

Polymorphisms in candidate genes and lipodystrophy and dyslipidemia. Aids Research and Human Retroviruses 28(6): 531, 2012

Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 59(2): 113-120, 2012

Lipodystrophy and dyslipidemia in human immunodeficiency virus-infected Thai patients receiving antiretroviral therapy. Journal of the Medical Association of Thailand 90(3): 452-458, 2007

Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy. Aids 27(4): 529-538, 2013

Dyslipidemia and lipodystrophy in HIV-infected Thai children on highly active antiretroviral therapy (HAART). Journal of the Medical Association of Thailand 88(7): 956-966, 2005

Relationship Between Polymerase Gamma (Polg) Polymorphisms and Antiretroviral Therapy-Induced Lipodystrophy in Hiv-1 Infected Patients: A Case-Control Study. Current Hiv Research 7(2): 244-253, 2009

Relationship between polymerase gamma (POLG) polymorphisms and antiretroviral therapy-induced lipodystrophy in HIV-1 infected patients: a case-control study. Current HIV Research 7(2): 244-253, 2009

Prediction of Cardiovascular Disease Risk Using Framingham and Data on Adverse Effect of Antiretroviral Drugs Risk Equation in Relation to Lipodystrophy in HIV Patients on Highly Active Antiretroviral Therapy. Journal of Global Infectious Diseases 10(4): 182-187, 2018

Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virus-infected patient following highly active antiretroviral therapy. Journal of the Cardiometabolic Syndrome 3(2): 111-114, 2008

Uridine metabolism in HIV-1-infected patients: effect of infection, of antiretroviral therapy and of HIV-1/ART-associated lipodystrophy syndrome. Plos One 5(11): E13896, 2011

Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study. Plos Medicine 10(10): E1001542, 2014

Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenetics and Genomics 17(9): 755-764, 2007

The nurse practitioner's role in managing dyslipidemia and other cardiovascular risk factors in HIV-infected patients: impact of antiretroviral therapy. Journal of the Association of Nurses in Aids Care 17(1): 7-17, 2006

Nutritional therapy to prevent dyslipidemia in patients starting antiretroviral therapy for human immunodeficiency virus. Journal of the American College of Cardiology 59(11): 989-990, 2012